PMID: 6172215Jan 1, 1981Paper

Chemotherapy of ovarian cancer directed by the human tumor stem cell assay

Cancer Chemotherapy and Pharmacology
D S AlbertsF L Meyskens

Abstract

The human tumor stem cell assay (HTSCA) has been used to study the in vitro sensitivity rates of anticancer drugs used in the treatment of 115 patients with previously untreated and relapsing ovarian cancer. The data from these studies have identified patterns of cross resistance and residual sensitivity between these agents, and have allowed the prospective selection of single agents possessing in vitro activity for the treatment of 32 patients with relapsing disease. cis-Platinum and vinblastine were the most active agents in vitro against ovarian TCFUs from both previously untreated and relapsing patients. Prior therapy with even one drug was associated with the acquisition of resistance to several classes of compounds (e.g., melphalan resistance was almost always associated with in vitro adriamycin resistance, P less than 0.001). A clinical trial yielding similar data would have required nearly 450 evaluable ovarian cancer patients. In 11 of 32 patients in vitro testing predicted sensitivity to single agents: eight of these had partial remissions for a predictive accuracy of 73%. In 33 instances the HTSCA had 100% accuracy in predicting the lack of clinical response. Thus, the HTSCA for advanced ovarian cancer appears to ha...Continue Reading

References

Jun 15, 1978·The New England Journal of Medicine·S E SalmonT E Moon
Mar 1, 1977·Gynecologic Oncology·C R StanhopeF Rutledge
Jul 29, 1977·Science·A W Hamburger, S E Salmon
Dec 1, 1978·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G BolisC Mangioni
Apr 8, 1976·The New England Journal of Medicine·J S Tobias, C T Griffiths
Oct 26, 1972·The New England Journal of Medicine·C M BagleyV T DeVita

❮ Previous
Next ❯

Citations

Feb 15, 1993·Cancer·B U SevinM Penalver
Mar 1, 1986·The Japanese Journal of Surgery·M ShibataK Morita
Dec 21, 2000·Current Oncology Reports·K Tewari, A Manetta
Jan 1, 1990·Gynecologic Oncology·L CarenzaR Prosperi Porta
Mar 1, 1985·International Journal of Cell Cloning·S E SingletaryG Blumenschein
Jul 15, 1983·American Journal of Obstetrics and Gynecology·E A SurwitS Leigh
Apr 1, 1997·American Journal of Obstetrics and Gynecology·B U Sevin, J P Perras
Oct 1, 1984·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·K BucksheeT N Chapekar
Mar 1, 1985·European Journal of Cancer & Clinical Oncology·R SilvestriniO Sanfilippo
Sep 15, 1983·International Journal of Cancer. Journal International Du Cancer·F L MeyskensS E Salmon
Dec 1, 1984·The British Journal of Surgery·G A TrotterI Taylor
Jun 16, 1983·The New England Journal of Medicine
Jan 20, 1983·The New England Journal of Medicine·P SelbyI Tannock
Jul 19, 2015·BMC Cancer·Ulrike KämmererChristoph Otto
May 1, 1990·The Journal of Urology·H B NiellM Brausi
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P Cortazar, B E Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.